 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Viragen, Inc.
|
-
Viragen Reports on Multiferon Anti-Viral Studies with U.S. Army Researchers
(09 Feb 2006)
Viragen, Inc. and its majority-owned subsidiary, Viragen International, Inc., reported on the progression of anti-viral studies using Multiferon® (multi-subtype, natural human alpha interferon) being conducted by the U.S. Army Medical Research ...
-
Viragen Reports Avian Transgenic Breakthrough: OVA(TM) System Expresses Interferon-Beta
(23 Jan 2006)
Viragen, Inc. announced that the Company's scientists, along with its collaborators at the Roslin Institute and Oxford BioMedica plc, have successfully achieved expression of significant quantities of the human protein, interferon beta-1a, in the ...
-
Lower-cost manufacturing for the production of many protein drugs by altering hens' genetic make-up
(20 Jul 2005)
Roslin Institute in Cancer Breakthrough
Scientists at Edinburgh's Roslin Institute have made a breakthrough in their battle to create designer eggs which may help to produce drugs to fight cancer.By altering hens' genetic make-up, the team has caused the synthesis in egg white of a ...
-
Viragen Reports Achievement of Key Avian Transgenics Milestone
(07 Jun 2005)
Anti-Cancer Antibody Expressed In Chicken Eggs Promises to Revolutionize Drug Production
Viragen, Inc., Roslin Institute (Scotland) and Oxford BioMedica PLC jointly announced a dramatic breakthrough in their pioneering project to develop Avian Transgenic Biomanufacturing with the report of a functional humanized antibody protein ...
-
Viragen Reports that Peptide Agreement Expires
(23 May 2005)
Viragen, Inc. announced that it has elected not to exercise an exclusive option to license VG104, the IEP 11 peptide, from the University of Miami. The IEP 11 peptide was being researched as a potential cancer therapeutic. In light of Viragen's ...
-
Viragen Licenses 'Anti-CD55 Antibody' Cancer Therapy from Cancer Research Technology
(11 May 2005)
Viragen, Inc. and Cancer Research Technology Limited (U.K.) announced a license agreement that provides Viragen with worldwide exclusive rights to commercialize the anti-CD55 antibody, which is currently in preclinical development for the treatment ...
-
Viragen Reports Advancement in Avian Transgenics Biomanufacturing
(21 Feb 2005)
Anti-cancer Antibody Expressed in Rooster
Viragen, Inc. announced an advancement in its program to develop avian transgenic biomanufacturing for the purpose of using chickens as bioreactors for the efficient and economical production of human pharmaceutical protein-based drugs in their ...
-
New Swedish Manufacturing Facility of Viragen for Multiferon(TM)
(23 Jul 2004)
Viragen confirmed that its Swedish manufacturing facility in Ersboda is on schedule to commence with the production of Multiferon(TM) in September. The Company has been upgrading and expanding its production capabilities as a result of a more ...
-
Producing Biotech Drugs Faster and Cheaper in the Eggs of Transgenic Hens
(09 Mar 2004)
Viragen and Scotland's Roslin Institute Announce Extended Agreement
Plantation, Fla. - Viragen, Inc. announced that the Company has extended its agreement with Scotland's Roslin Institute to develop Avian Transgenic Technology. The agreement, extended by two years, continues to provide Viragen with the worldwide ...
|
|
|
|
|
Top
